7-aminopyrazolo[3,4-c]pyridine | 948029-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 7-aminopyrazolo[3,4-c]pyridine
• 英文别名: 1H-Pyrazolo[3,4-C]pyridin-7-amine
• CAS: 948029-46-7
• 化学式: C₆H₆N₄
• mdl: MFCD13175915
• 分子量: 134.14
• InChiKey: SGFRUQZYZBPQCJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.480±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 7-aminopyrazolo[3,4-c]pyridine 在 氨 作用下， 以 甲醇 为溶剂， 反应 13.0h， 以92%的产率得到7-acetamido-1H-pyrazolo[3,4-c]pyridine
  参考文献：
  名称：

  Synthesis and tautomerism study of 7-substituted pyrazolo[3,4-c]pyridines

  摘要：

  A number of 7-substituted pyrazolo[3,4-c]pyridine derivatives have been synthesized in order to investigate the N1-N2 tautomerism within this class of biologically interesting compounds. Tautomeric equilibrium has been studied using NMR C-13, N-15 chemical shifts and heteronuclear H-1-N-15 and H-1-C-13 spin-spin couplings, in conjunction with X-ray crystallography. The N1 tautomer predominates in DMF solution in all the compounds tested. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2006.09.081
• 作为产物：
  描述：

  2-氨基-3-硝基-4-甲基吡啶 在 potassium acetate 、 乙酸酐 、 铁粉 、 溶剂黄146 、 亚硝酸异戊酯 作用下， 以 溶剂黄146 、 丙酮 、 甲苯 、 苯 为溶剂， 反应 33.5h， 生成 7-aminopyrazolo[3,4-c]pyridine
  参考文献：
  名称：

  Synthesis of 7-Aminopyrazolo[3,4-c]pyridine as a Probe for the Preparation of Compounds of Pharmacological Interest

  摘要：

  DOI：

  10.3987/com-02-9621

文献信息

• [EN] BTK INHIBITORS<br/>[FR] INHIBITEURS DE BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095099A1

  公开（公告）日：2015-06-25

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

  本发明提供了根据公式I或其药用可接受盐的Bruton酪氨酸激酶（Btk）抑制剂化合物，或其药用可接受盐，或包含这些化合物的药物组合物，以及它们在治疗中的应用。具体而言，本发明涉及在治疗Btk介导的疾病中使用Btk抑制剂化合物。
• 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
  申请人：Arnold D. Lee

  公开号：US20060235031A1

  公开（公告）日：2006-10-19

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  公式如下的化合物及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，能够抑制IGF-1R酶，适用于治疗和/或预防增生性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病以及中枢神经系统疾病和疾病。
• 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
  申请人：Arnold Lee D.

  公开号：US20090118499A1

  公开（公告）日：2009-05-07

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该公式化合物及其药学上可接受的盐，其中X1、X2、X3、X4、X5、X6、X7、R1和Q1的定义如下，可抑制IGF-1R酶，用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病和中枢神经系统疾病和病症。
• Bicyclic protein kinase inhibitors
  申请人：Crew Philip Andrew

  公开号：US20070149521A1

  公开（公告）日：2007-06-28

  Compounds of the Formula and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该公式的化合物及其药用可接受盐，其中X1，X2，X3，X4，X5，X6，X7，R1和Q1在此定义，抑制蛋白激酶酶，并且对于治疗和/或预防过度增殖性疾病，例如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统疾病和情况，中枢神经系统疾病和情况是有用的。
• 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2168968A1

  公开（公告）日：2010-03-31

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  式 (I) 的化合物 及其药学上可接受的盐，其中 X1、X2、X3、X4、X5、X6、X7、R1 和 Q1 在此定义，抑制 IGF-1R 酶，可用于治疗和/或预防过度增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和病症、中枢神经系统疾病和病症。